DexCom, Inc. (NASDAQ:DXCM) Receives $98.00 Consensus PT from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $98.00.

A number of research analysts have commented on the company. Citigroup boosted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group upped their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company lifted their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom in the 4th quarter worth approximately $3,334,000. First Hawaiian Bank lifted its position in DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock worth $1,801,000 after purchasing an additional 19,629 shares during the period. Nordea Investment Management AB lifted its position in DexCom by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock worth $6,271,000 after purchasing an additional 2,183 shares during the period. GAMMA Investing LLC boosted its stake in DexCom by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 8,258 shares of the medical device company’s stock valued at $642,000 after purchasing an additional 2,665 shares in the last quarter. Finally, Versant Capital Management Inc acquired a new position in shares of DexCom during the 4th quarter valued at $25,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

NASDAQ:DXCM opened at $77.76 on Wednesday. The firm’s fifty day simple moving average is $76.93 and its 200 day simple moving average is $79.30. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market capitalization of $30.37 billion, a price-to-earnings ratio of 46.56, a PEG ratio of 2.36 and a beta of 1.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.